NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Osteitis Deformans


Return to Library

Free Osteitis Deformans Articles


Studies from University of Nottingham in the area of osteitis deformans described



2009 JUN 2 - (NewsRx.com) -- "Mutations affecting the ubiquitin-associated (UBA) domain of sequestosome 1 (SQSTM1/p62) are commonly found in Paget's disease of bone (PDB) and impair SQSTM1's ability to bind ubiquitin, resulting in dysregulated NF-kappa B signaling. In contrast, non-UBA domain mutations are rarer, and little is known about how they manifest their effects," researchers in Nottingham, the United Kingdom report.

"We present the first characterization at the molecular, cellular, and functional level of a non-UBA domain missense mutation (A381V) of SQSTM1. Direct sequencing of exon 7 of the SQSTM1 gene in all Italian PDB patient detected a heterozygous C to T transversion at position 1182, resulting in all alanine to valine substitution at codon 381. Pull-down assays showed the non-UBA region of SQSTM1. that contains A381 is important in mediating ubiquitin-binding affinity and that the A381V mutation exerts weak negative effects on ubiquitin binding. Structural and binding analyses of longer UBA constructs containing A381, using NMR spectroscopy and circular dichroism, showed this region of the protein to be largely unstructured and confirmed its contribution to increased ubiquitin-binding, affinity. Co-transfections of U20S cells showed that the A381V mutant SQSTM1 co-localized with ubiquitin with a cellular phenotype indistinguishable from wildtype. Finally, effects of the wildtype and mutant SQSTM1 on NF-kappa B signaling were assessed in HEK293 cells co-transfected with an NF-kappa B luciferase reporter construct," wrote D. Najat and colleagues, University of Nottingham.

The researchers concluded: "A381V mutant SQSTM1 produced a level of activation of NF-kappa B signaling greater than wildtype and similar to that of UBA domain mutants, indicating, that non-UBA and UBA domain mutations may exert their effects through a common mechanism involving dysregulated NF-kappa B signaling."

Najat and colleagues published their study in the Journal of Bone and Mineral Research (Characterization of a Non-UBA Domain Missense Mutation of Sequestosome 1 (SQSTM1) in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2009;24(4):632-642).

For additional information, contact R. Layfield, University of Nottingham, School Medical, School Biomedical Science, Nottingham NG7 2UH, UK.

Publisher contact information for the Journal of Bone and Mineral Research is: American Society Bone & Mineral Research, 2025 M St., N W, Ste. 800, Washington, DC 20036-3309, USA.

Keywords: United Kingdom, Nottingham, Bone, Osteitis Deformans, Paget Disease, University of Nottingham.

This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2009, Life Science Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login